Table 1 Baseline characteristics of 382 HCC patients in this study
Characteristic | Values |
|---|---|
Gender, male, n (%) | 295 (77.2%) |
Age at diagnosis, years, median (range) | 58.0 (19.0–87.0) |
Tumor number, median (range) | 1.0 (1.0–10.0) |
Capsule, n (%) | 280 (73.3%) |
Tumor grade, median (range) | 3.0 (1.0–4.0) |
Macrovascular invasion, n (%) | 41 (10.7%) |
Microvascular invasion, n (%) | 121 (31.7%) |
Tumor size, cm, median (range) | 4.3 (0.7–20.0) |
Cirrhosis, n (%) | 225 (58.9%) |
Ascites, n (%) | 26 (6.8%) |
HBV alone, n (%) | 228 (59.7%) |
HCV alone, n (%) | 63 (16.5%) |
HBV + HCV, n (%) | 36 (9.4%) |
NBNC, n (%) | 55 (14.4%) |
Alcoholism (%) | 97 (25.4%) |
UGT2B28 rs2132039 TT, n (%) | 181 (47.4%) |
UGT2B28 rs2132039 Non-TT, n (%) | 201 (52.6%) |
Prothrombin time, second, median (rang) | 11.9 (9.0–19.5) |
AST, U/L, median (range) | 37.0 (11.0–559.0) |
ALT, U/L, median (range) | 39.0 (7.0–749.0) |
Bilirubin, mg/dL, median (range) | 0.8 (0.3–15.3) |
Albumin, g/dL, median (range) | 4.1 (1.7–5.1) |
Creatinine, mg/dL, median (range) | 1.0 (0.4–15.4) |
Alpha-fetoprotein, ng/mL, median (range) | 26.5 (1.0–685,353.0) |
Recurrent, n (%) | 212 (55.5%) |
Recurrent time, month, median (range) | 12.9 (1.0–114.7) |
Metastasis, n (%) | 73 (19.1%) |
Metastatic time, month, median (range) | 13.0 (1.0–99.2) |
Death, n (%) | 47 (12.3%) |
Survival time, month, median (range) | 22.5 (0.1–73.7) |